Posted by Michael Wonder on 10 Jan 2024
European Commission approves Pfizer’s Talzenna in combination with Xtandi for adult patients with metastatic castration resistant prostate cancer
8 January 2024 - Talzenna is the first and only PARP inhibitor approved in combination with standard of care Xtandi for metastatic castration resistant prostate cancer patients in the European Union.
Pfizer today announced that the European Commission has approved Talzenna (talazoparib), an oral poly ADP ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with metastatic castration resistant prostate cancer in whom chemotherapy is not clinically indicated.
